Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and prescribers, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Pharmacy edition

Latest Issues

April Bulletin Vol 25-07 (PDF)
New Exception Status Product: Osnuvo (teriparatide); Criteria Updates: Bimzelx (bimekizumab), Imbruvica (ibrutinib), Tagrisso (osimertinib), Venclexta (venetoclax), Cipro (ciprofloxacin and generics), Levaquin (levofloxacin and generics), Avelox (moxifloxacin and generics), Norfloxacin; Change in Benefit Status; New Benefits

March Bulletin Vol 25-06 (PDF)
Infliximab IV IV (Inflectra) Changes and New Infliximab IV Products ,New Exception Status Products; Sohonos (palovarotene); Ticagrelor (Brilinta and generic brands); Truqap (capivasertib) Change in Benefit Status
New Benefits

March Bulletin Vol 25-05 (PDF)
Infliximab IV (Inflectra) Changes Changes for Submission of Claims over $9,999.99.

March Bulletin Vol 25-04 (PDF)
Pharmacists' Administration of Respiratory Syncytial Virus (RSV) Vaccine in Long-term Care Facilities and Residential Care Facilities

February Bulletin Vol 25-03 (PDF)
New Exception Status Benefits: Koselugo (selumetinib), Remsima SC (infliximab), Welireg (belzutifan); Criteria Update: Kerendia (finerenone); Coverage Period Updates for Biologics and Janus Kinase (JAK) Inhibitors.

February Bulletin Vol 25-02 (PDF)
Nova Scotia Formulary Updates, Physician Assistant and Podiatrist Prescribing

January Bulletin Vol 25-01 (PDF)
New Exception Status Products: Amvuttra (vutrisiran), Orladeyo (berotralstat hydrochloride) Criteria Update, Verzenio (abemaciclib) New Benefits Generic Drug Pricing Reminder Auditor’s Corner

Prescriber edition

Latest Issues

April Bulletin Vol 25-04 (PDF)
New Exception Status Product: Osnuvo (teriparatide); Criteria Updates: Bimzelx (bimekizumab), Imbruvica (ibrutinib), Tagrisso (osimertinib), Venclexta (venetoclax), Cipro (ciprofloxacin and generics), Levaquin (levofloxacin and generics), Avelox (moxifloxacin and generics), Norfloxacin; Change in Benefit Status; New Benefits

March Bulletin Vol 25-03 (PDF)
Infliximab IV (Inflectra) Changes and New Infliximab IV Products; New Exception Status Products Sohonos (palovarotene), Ticagrelor (Brilinta and generic brands), Truqap (capivasertib); Change in Benefit Status, New Benefits

February Bulletin Vol 25-02 (PDF)
New Exception Status Benefits: Koselugo (selumetinib), Remsima SC (infliximab), Welireg (belzutifan); Criteria Update: Kerendia (finerenone); Coverage Period Updates for Biologics and Janus Kinase (JAK) Inhibitors.

January Bulletin Vol 25-01 (PDF)
New Exception Status Products: Amvuttra (vutrisiran), Orladeyo (berotralstat hydrochloride) Criteria Update, Verzenio (abemaciclib) New Benefits